Search
Human C1-esterase inhibitor
go.drugbank.com/drugs/DB06404ApprovedInvestigational[L16586, L16606] This drug is indicated for prophylaxis and treatment of Hereditary Angioedema (HAE), a human genetic disorder caused by a shortage of C1 inhibitor activity that results in an overreaction … The disease is characterized by acute attacks of painful, and in some cases, fatal swelling of several soft tissues or edema, which may last up to five days when untreated.[L16586, L16606]
Categories: Drugs Used in Hereditary AngioedemaStem bromelain
go.drugbank.com/drugs/DB12249ApprovedThis action allows bromelain to demonstrate a wide range of therapeutic benefits ranging from cardiovascular to anticancer therapy - but the specific mechanisms of action by which it can elicit these effects
Onion
go.drugbank.com/drugs/DB10548ApprovedOnion allergenic extract is used in allergenic testing.
Mixtures: NOSKAR 100 MG/50 IU/10 MG / G, JEL 120 G, NOSKAR 100 MG/50 IU/10 MG / G, JEL 50 GValganciclovir
go.drugbank.com/drugs/DB01610ApprovedInvestigationalValganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. … As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases.
Products: RUNAVIR®450 MG, VALGOVIR® 450 MGIcotrokinra
go.drugbank.com/drugs/DB21724ApprovedInvestigationalIcotrokinra is a first-in-class, targeted oral peptide and interleukin-23 (IL-23) receptor antagonist. … It was jointly discovered and developed by Protagonist and Johnson & Johnson[L56118] and provides a novel, oral treatment option for patients requiring systemic therapy for plaque psoriasis.
Nifurtimox
go.drugbank.com/drugs/DB11820ApprovedInvestigationalIt is commonly known as American Trypanosomiasis. … [L15366] The CDC estimates that approximately 8 million people in Central America, South America, and Mexico are infected with T. cruzi, without symptoms.
Spiramycin
go.drugbank.com/drugs/DB06145ApprovedInvestigationalWithdrawnSpiramycin is a 16-membered ring macrolide discovered in 1952 as a product of Streptomyces ambofaciens that has been available in oral formulations since 1955, and parenteral formulations since 1987.
Mixtures: METİRASİN 1,5 MIU/250 MG FILM TABLET, 14 ADET, METİRASİN 1,5 MIU/250 MG FİLM KAPLI TABLET, 10 ADETPitolisant
go.drugbank.com/drugs/DB11642ApprovedInvestigational[A32024] Pitolisant therapy was also effective in treating refractory sleepiness in adolescent patients with narcolepsy, where it decreased ESS score and increased the mean sleep onset latency. … FDA approved the use of pitolisant in 2019 for excessive daytime sleepiness (EDS) associated with narcolepsy in adults.[L8063]
Yellow fever vaccine
go.drugbank.com/drugs/DB10805ApprovedInvestigationalThe World Health Organization recommends routine vaccination in countries where Yellow Fever is endemic, and for travellers going to endemic areas as proof of vaccination is often a requirement at border … It is composed of two live, attenuated strains of yellow fever virus, 17D-204 and 17DD, which have been shown to elicit an immune response identical to that induced by wild-type infection [FDA Label, A32118
Fospropofol
go.drugbank.com/drugs/DB06716ApprovedIllicitInvestigationalWithdrawnUnlike propofol, does not cause injection-site pain as it is unable to activate TRPA1. FDA approved in December 2008. … Fospropofol is a Schedule IV controlled substance in the United States under the Controlled Substances Act.